Your browser is no longer supported. Please, upgrade your browser.
Settings
HARP Harpoon Therapeutics, Inc. daily Stock Chart
HARP [NASD]
Harpoon Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.25 Insider Own0.60% Shs Outstand24.83M Perf Week-2.11%
Market Cap403.56M Forward P/E- EPS next Y-2.04 Insider Trans-73.93% Shs Float22.18M Perf Month-11.55%
Income-54.50M PEG- EPS next Q-0.48 Inst Own77.60% Short Float2.01% Perf Quarter41.59%
Sales8.00M P/S50.45 EPS this Y-123.30% Inst Trans0.42% Short Ratio2.51 Perf Half Y14.04%
Book/sh3.36 P/B4.83 EPS next Y-3.00% ROA-34.20% Target Price- Perf Year7.91%
Cash/sh4.95 P/C3.28 EPS next 5Y- ROE-53.60% 52W Range10.27 - 25.02 Perf YTD9.80%
Dividend- P/FCF- EPS past 5Y- ROI-61.80% 52W High-35.09% Beta-
Dividend %- Quick Ratio5.40 Sales past 5Y- Gross Margin- 52W Low58.13% ATR1.01
Employees67 Current Ratio5.40 Sales Q/Q200.00% Oper. Margin- RSI (14)46.46 Volatility4.64% 5.63%
OptionableYes Debt/Eq0.00 EPS Q/Q9.30% Profit Margin- Rel Volume0.30 Prev Close16.14
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume177.62K Price16.24
Recom1.40 SMA20-6.32% SMA50-4.60% SMA2008.40% Volume53,035 Change0.62%
May-22-20Initiated Piper Sandler Overweight $35
Feb-28-20Initiated SunTrust Buy
Feb-03-20Initiated H.C. Wainwright Buy $28
Nov-14-19Initiated ROTH Capital Buy $25
May-24-19Resumed Citigroup Buy $23
Apr-23-19Initiated Robert W. Baird Outperform
Mar-05-19Initiated Wedbush Outperform $23
Jul-05-20 04:17PM  
Jul-02-20 07:30AM  
Jun-17-20 07:30AM  
Jun-11-20 07:30AM  
May-29-20 08:00AM  
May-22-20 07:30AM  
May-11-20 06:35AM  
May-06-20 04:05PM  
Apr-27-20 06:30AM  
Apr-01-20 07:30AM  
Mar-26-20 12:54PM  
Mar-12-20 04:05PM  
02:30PM  
Mar-05-20 07:30AM  
Feb-20-20 07:30AM  
Jan-25-20 07:38PM  
08:55AM  
Dec-19-19 10:38PM  
Dec-04-19 09:29AM  
Nov-26-19 07:30AM  
Nov-21-19 04:00AM  
Nov-12-19 04:05PM  
12:46PM  
Nov-06-19 04:05PM  
Oct-29-19 12:30PM  
Oct-22-19 04:05PM  
Sep-19-19 01:18PM  
Aug-28-19 04:05PM  
Aug-05-19 04:05PM  
Jul-31-19 04:05PM  
Jul-01-19 02:08PM  
Jun-20-19 04:05PM  
May-26-19 10:44AM  
May-24-19 02:38PM  
May-10-19 02:55PM  
May-09-19 08:30AM  
Apr-22-19 12:28AM  
Apr-18-19 07:30AM  
Apr-09-19 05:49PM  
Apr-04-19 09:17AM  
Mar-14-19 04:05PM  
Mar-13-19 04:07PM  
Mar-07-19 04:05PM  
10:11AM  
Mar-05-19 11:40AM  
Feb-25-19 02:54PM  
09:47AM  
Feb-20-19 07:30AM  
Feb-14-19 02:25AM  
Feb-11-19 04:16PM  
10:38AM  
Feb-03-19 11:00AM  
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536, which is in Phase I/IIa clinical trial for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wesche HolgerChief Scientific OfficerJul 01Option Exercise0.6010,0006,00062,669Jul 02 07:18 PM
Wesche HolgerChief Scientific OfficerJul 01Sale16.2010,000161,98952,669Jul 02 07:18 PM
Arix Bioscience plc10% OwnerMay 28Sale21.33366,5917,820,9262,193,704May 29 04:32 PM
Arix Bioscience plc10% OwnerMay 27Sale22.3912,064270,1442,560,295May 29 04:32 PM
Sacks NatalieChief Medical OfficerMay 18Option Exercise2.121,5223,22747,276May 20 06:34 PM
Sacks NatalieChief Medical OfficerMay 18Sale14.771,52222,47945,754May 20 06:34 PM
Wesche HolgerChief Scientific OfficerMay 12Option Exercise0.601,40084054,069May 13 08:45 PM
Wesche HolgerChief Scientific OfficerMay 12Sale14.091,40019,72052,669May 13 08:45 PM
Wesche HolgerChief Scientific OfficerMay 11Option Exercise0.601,00060053,669May 11 09:37 PM
Wesche HolgerChief Scientific OfficerMay 11Sale14.071,00014,06552,669May 11 09:37 PM
Wesche HolgerChief Scientific OfficerMay 08Option Exercise0.601,00060053,669May 11 09:37 PM
Wesche HolgerChief Scientific OfficerMay 08Sale14.001,00014,00052,669May 11 09:37 PM
Wesche HolgerChief Scientific OfficerMay 07Option Exercise0.605,3503,21058,019May 11 09:37 PM
Wesche HolgerChief Scientific OfficerMay 07Sale14.135,35075,57652,669May 11 09:37 PM
Sacks NatalieChief Medical OfficerMay 01Option Exercise2.125,82612,35151,580May 05 04:35 PM
Sacks NatalieChief Medical OfficerMay 01Sale12.075,82670,30145,754May 05 04:35 PM
Wesche HolgerChief Scientific OfficerApr 28Option Exercise0.601,25075053,919Apr 30 04:58 PM
Wesche HolgerChief Scientific OfficerApr 28Sale14.051,25017,56552,669Apr 30 04:58 PM
Sacks NatalieChief Medical OfficerApr 17Option Exercise2.121,0212,16546,775Apr 17 07:10 PM
Sacks NatalieChief Medical OfficerApr 17Sale12.081,02112,33045,754Apr 17 07:10 PM
Sacks NatalieChief Medical OfficerApr 16Option Exercise2.125001,06046,254Apr 17 07:10 PM
Sacks NatalieChief Medical OfficerApr 16Sale12.005006,00045,754Apr 17 07:10 PM
Sacks NatalieChief Medical OfficerApr 13Option Exercise2.124,5569,65950,310Apr 15 04:48 PM
Sacks NatalieChief Medical OfficerApr 13Sale12.064,55654,95945,754Apr 15 04:48 PM
Sacks NatalieChief Medical OfficerApr 07Option Exercise2.125701,20846,324Apr 08 06:10 PM
Sacks NatalieChief Medical OfficerApr 07Sale12.005706,84045,754Apr 08 06:10 PM
Sacks NatalieChief Medical OfficerApr 06Option Exercise2.127001,48446,454Apr 08 06:10 PM
Sacks NatalieChief Medical OfficerApr 06Sale12.007008,40145,754Apr 08 06:10 PM
Sacks NatalieChief Medical OfficerMar 17Option Exercise2.121,5203,22247,274Mar 18 05:28 PM
Sacks NatalieChief Medical OfficerMar 17Sale12.001,52018,24045,754Mar 18 05:28 PM
Sacks NatalieChief Medical OfficerMar 16Option Exercise2.121245,755Mar 18 05:28 PM
Sacks NatalieChief Medical OfficerMar 16Sale12.0011245,754Mar 18 05:28 PM
Sacks NatalieChief Medical OfficerMar 02Option Exercise2.125,82612,35151,580Mar 03 09:31 PM
Sacks NatalieChief Medical OfficerMar 02Sale14.685,82685,52645,754Mar 03 09:31 PM
Sacks NatalieChief Medical OfficerFeb 18Option Exercise2.121,5213,22547,275Feb 20 05:11 PM
Sacks NatalieChief Medical OfficerFeb 18Sale15.001,52122,81545,754Feb 20 05:11 PM
Sacks NatalieChief Medical OfficerFeb 03Option Exercise2.125,82612,35151,580Feb 04 08:11 PM
Sacks NatalieChief Medical OfficerFeb 03Sale13.905,82681,00645,754Feb 04 08:11 PM
Erbez GeorgiaChief Financial OfficerJan 21Buy14.096,70094,4186,700Jan 23 08:34 AM
Sacks NatalieChief Medical OfficerJan 16Option Exercise2.121,5213,22547,275Jan 21 08:05 PM
Sacks NatalieChief Medical OfficerJan 16Sale14.941,52122,72545,754Jan 21 08:05 PM
Wesche HolgerChief Scientific OfficerJan 02Option Exercise0.6010,0006,00062,669Jan 06 09:55 PM
Sacks NatalieChief Medical OfficerJan 02Option Exercise2.125,82612,35151,580Jan 06 09:46 PM
Sacks NatalieChief Medical OfficerJan 02Sale14.185,82682,60045,754Jan 06 09:46 PM
Wesche HolgerChief Scientific OfficerJan 02Sale14.4010,000143,98752,669Jan 06 09:55 PM
Baeuerle PatrickDirectorDec 27Sale15.9887,3791,396,281262,136Dec 30 05:32 PM
Chin MarkDirectorDec 17Sale16.8312,476209,9692,572,359Dec 17 09:23 PM
Arix Bioscience plc10% OwnerDec 17Sale16.8312,476209,9692,572,359Dec 17 07:20 PM
Sacks NatalieChief Medical OfficerDec 16Option Exercise2.121,5213,22547,275Dec 18 04:14 PM
Sacks NatalieChief Medical OfficerDec 16Sale17.021,52125,88845,754Dec 18 04:14 PM
Arix Bioscience plc10% OwnerDec 16Sale17.0213,080222,6802,584,835Dec 17 07:20 PM
Chin MarkDirectorDec 16Sale17.0213,080222,6802,584,835Dec 17 09:23 PM
Chin MarkDirectorDec 13Sale17.2111,002189,3412,597,915Dec 17 09:23 PM
Arix Bioscience plc10% OwnerDec 13Sale17.2111,002189,3412,597,915Dec 17 07:20 PM
Chin MarkDirectorDec 10Sale16.91131,6962,227,0192,608,917Dec 10 08:07 PM
Arix Bioscience plc10% OwnerDec 10Sale16.91131,6962,227,0192,608,917Dec 10 07:27 PM
Arix Bioscience plc10% OwnerDec 09Sale18.16103,7541,884,4452,740,613Dec 10 07:27 PM
Chin MarkDirectorDec 09Sale18.16103,7541,884,4452,740,613Dec 10 08:07 PM
Chin MarkDirectorDec 06Sale19.1547,752914,2222,844,367Dec 10 08:07 PM
Arix Bioscience plc10% OwnerDec 06Sale19.1547,752914,2222,844,367Dec 10 07:27 PM
Erbez GeorgiaChief Financial OfficerDec 04Option Exercise2.1247,292100,25947,292Dec 06 04:41 PM
Sacks NatalieChief Medical OfficerDec 02Option Exercise2.125,82612,35151,580Dec 04 04:42 PM
Sacks NatalieChief Medical OfficerDec 02Sale17.985,826104,75145,754Dec 04 04:42 PM
Sacks NatalieChief Medical OfficerNov 18Option Exercise2.1218,25238,69464,006Nov 19 04:24 PM
Sacks NatalieChief Medical OfficerNov 18Sale13.3718,252243,96445,754Nov 19 04:24 PM